Importantly, the risk of hepatocellular carcinoma was also decreased in patients heterozygous (OR = 0.65) and homozygous (OR = 0.28) for the HSD17B13 rs72613567:TA allele (Abul-Husn et al., 2018). This evidence concerns the gene HSD17B13 and hepatocellular carcinoma.